SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-02-12
Accession Number: 0001493152-26-006407
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226006407/forms-1.htm

Chunk 20 of 83
Word Count: 1493
Character Count: 10092

Document Content:

approved or cleared will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace. Proposing, negotiating and implementing an economically viable product or technology acquisition or license is a lengthy and complex process. Other companies, including those with substantially greater financial, marketing and sales resources, may compete with us for the acquisition or license of approved or cleared product candidates. We may not be able to acquire or license the rights to additional approved or cleared product candidates on terms that we find acceptable, or at all. If we are unable to develop suitable potential product candidates through internal research programs or by obtaining rights from third parties, it could have a material adverse effect on our business, financial condition and results of operations. may acquire other businesses which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations.

part of our business strategy, we may in the future make acquisitions or investments in complementary companies, product candidates or
technologies that we believe fit within our business model and can address the needs of our customers and potential customers. In the
future, we may not be able to acquire and integrate other companies, product candidates or technologies in a successful manner. We may
not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all.
In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in
identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. If we do complete acquisitions, we
may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we
complete could be viewed negatively by our customers, investors and industry analysts.

Future
acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable
assets acquired. We may have to pay cash, incur debt or issue equity securities to pay for any such acquisition, each of which could
adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such acquisitions
would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations
and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future
results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses
associated with an acquisition. Furthermore, acquisitions may require large, one-time charges and can result in increased debt or contingent
liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of
amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations.
We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions.

Also,
the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint
venture or acquisition may be prohibited. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances
of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which
could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect
that any such transactions might have on our operating results.

General
economic conditions may adversely affect our business.

Adverse
worldwide economic conditions may negatively impact our business. A significant change in the liquidity or financial condition of our
customers could cause unfavorable trends in their purchases and also in our receivable collections, and additional allowances may be
required, which could adversely affect our business, financial condition and results of operations. Adverse worldwide economic conditions,
including tariff and trade wars, may also adversely impact our suppliers’ ability to provide us with materials and components,
which could have a material adverse effect on our business, financial condition and results of operations.

Business
disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our
operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons,
fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we
are predominantly self-insured. We rely on third-party manufacturers to produce our product candidates. Our ability to obtain clinical
supplies of our product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster
or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial
condition and increase our costs and expenses.

Risks
Related to Our Intellectual Property and Technology

will be required to comply with our obligations in our intellectual property licenses and other agreements with third parties.

we fail to comply with our obligations in our intellectual property licenses and other agreements with third parties, we could lose license
rights that are important to our business. We are not currently party to any intellectual property license agreement with any third parties,
but we anticipate that in-licensing and co-development will be strategies that we utilize as we continue to pursue our growth strategy.
We expect to enter into licenses and co-development and other agreements in the future, and we expect these agreements to impose, various
diligences, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, the licensor
may have the right to terminate the license, in which event we might not be able to market any product that is covered by the licensed
patents.

may need to resort to litigation to enforce or defend our intellectual property rights, including any patents issued to us. If a competitor
or collaborator files a patent application claiming technology also invented by us, in order to protect our rights, we may have to participate
in an expensive and time-consuming interference proceeding before the United States Patent and Trademark Office. We cannot guarantee
that our product candidates will be free of claims by third parties alleging that we have infringed their intellectual property rights.
Third parties may assert that we are employing their proprietary technologies without authorization and they may resort to litigation
to attempt to enforce their rights. Third parties may have or obtain patents in the future and claim that the use of our technology or
any of our product candidates infringes their patents. We may not be able to develop or commercialize combination product candidates
because of patent protection others have. Our business will be harmed if we cannot obtain a necessary or desirable license, can obtain
such a license only on terms we consider to be unattractive or unacceptable, or if we are unable to redesign our product candidates or
processes to avoid actual or potential patent or other intellectual property infringement. Obtaining, protecting and defending patent
and other intellectual property rights can be expensive and may require us to incur substantial costs, including the diversion of management
and technical personnel. An unfavorable ruling in patent or intellectual property litigation could subject us to significant liabilities
to third parties, require us to cease developing, manufacturing or selling the affected product candidates or using the affected processes,
require us to license the disputed rights from third parties, or result in awards of substantial damages against us.

There
can be no assurance that we would prevail in any intellectual property infringement action, will be able to obtain a license to any third-party
intellectual property on commercially reasonable terms, successfully develop non-infringing alternatives on a timely basis, or license
non-infringing alternatives, if any exist, on commercially reasonable terms. Any significant intellectual property impediment to our
ability to develop and commercialize our product candidates could seriously harm our business and prospects.

we are unable to adequately protect our proprietary technology or obtain and maintain issued patents that are sufficient to protect our
product candidates, product candidates, and methods others could compete against us more directly, which could harm our business, financial
condition and results of operations.

Our
intellectual property and proprietary rights are important to our ability to remain competitive and for the success of our product candidates
and our business. Patent protection can be limited and not all intellectual property is or can be patented. Our commercial success may
depend in part on our ability to obtain and maintain patents and other intellectual property rights in the United States and elsewhere,
and protect our proprietary technologies. If we do not adequately protect our intellectual property and proprietary technologies, competitors
may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and profitability.